IDH2 and cancer: Mutation in IDH2 leads to increased generation of oncogenic metabolite 2-hydroxyglutarate (2-HG), which promotes carcinogenesis by causing alterations in epigenetics, whereas wild-type IDH2 promotes cancer cell survival and proliferation through enhancing the reductive TCA cycle for the utilization of glutamine for lipid synthesis and increasing the antioxidant capacity of the cancer cells to counteract oxidative stress [15].